David A Proia

Summary

Publications

  1. ncbi Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 6:e18552. 2011
  2. ncbi Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
  3. ncbi Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
  4. ncbi Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
  5. ncbi Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
  6. ncbi Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
    Ronald K Blackman
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e29798. 2012

Collaborators

  • Guri Giaever
  • Richard C Bates
  • Suqin He
  • Yumiko Wada
  • Jaime Acquaviva
  • Jim Sang
  • Ronald K Blackman
  • Donald L Smith
  • Chaohua Zhang
  • Julie C Friedland
  • Manuel Sequeira
  • Weiwen Ying
  • Ayesha A Shafi
  • Nancy L Weigel
  • James Barsoum
  • Corey Nislow
  • Shuxia Ye
  • Kevin P Foley
  • AurĂ©lie Jonneaux
  • Luisa Shin Ogawa
  • Marinella Gebbia
  • Noriaki Tatsuta
  • Jane Kepros
  • Kahlin Cheung-Ong
  • Zhenjian Du
  • Jerome Kluza
  • Lijun Sun
  • Philippe Marchetti
  • Dan Zhou
  • Patricia E Rao
  • Takayo Inoue
  • Keizo Koya
  • Jamie Acquaviva

Detail Information

Publications6

  1. ncbi Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 6:e18552. 2011
    ..Overall, our findings support Hsp90 inhibition as a novel therapeutic approach for combating diseases dependent on JAK/STAT signaling, with the multimodal action of ganetespib demonstrating advantages over JAK-specific inhibitors...
  2. ncbi Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
    David A Proia
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Invest New Drugs 30:2201-9. 2012
    ..Taken together, these findings provide preclinical evidence for the use of this combination to treat patients with advanced NSCLC...
  3. ncbi Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
    Weiwen Ying
    Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA
    Mol Cancer Ther 11:475-84. 2012
    ....
  4. ncbi Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
    Jaime Acquaviva
    Synta Pharmaceuticals, Corp, Lexington, MA 02421, USA
    Mol Cancer Ther 11:2633-43. 2012
    ..Taken together, these data underscore the promise of ganetespib as a single-agent or combination treatment in KRAS-driven lung tumors...
  5. ncbi Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
    Suqin He
    Synta Pharmaceuticals Corp, Lexington, MA 02421, USA
    Int J Oncol 42:35-43. 2013
    ..Together these data suggest that further investigation of ganetespib as a new therapeutic treatment for prostate cancer patients is warranted...
  6. ncbi Mitochondrial electron transport is the cellular target of the oncology drug elesclomol
    Ronald K Blackman
    Synta Pharmaceuticals Corp, Lexington, Massachusetts, United States of America
    PLoS ONE 7:e29798. 2012
    ....